# Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
Canonical URL: https://biopharmsignal.com/news/ENSC/ensysce-biosciences-receives-eu-patent-expanding-its-first-in-class-adhd-therapy-with-built-in-abuse-and-overdose-protection
Ticker: ENSC
Company: Ensysce Biosciences
Source: Ensysce Biosciences
Published: 2026-01-08 13:00 EST
Original Source URL: https://ir.ensysce.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-14 12:00 EST — [Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant](https://biopharmsignal.com/news/ENSC/ensysce-biosciences-awarded-5-3-million-installment-in-nida-funding-completing-m-ee1ecc0e) — Source: Ensysce Biosciences
- 2026-06-26 12:00 EST — [Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study](https://biopharmsignal.com/news/ENSC/ensysce-biosciences-enrolls-first-patient-in-final-phase-of-pf614-mpar-102-clini-3e521199) — Source: Ensysce Biosciences
- 2026-05-15 20:15 EST — [Ensysce Biosciences Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/ENSC/ensysce-biosciences-reports-first-quarter-2026-financial-results) — Source: Ensysce Biosciences
- 2026-05-12 12:00 EST — [Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology](https://biopharmsignal.com/news/ENSC/ensysce-biosciences-announces-expansion-of-patent-protection-for-groundbreaking-mpar-r-overdose-protection-technology) — Source: Ensysce Biosciences
- 2026-05-08 12:00 EST — [Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam](https://biopharmsignal.com/news/ENSC/ensysce-biosciences-ceo-presents-at-inaugural-clinical-pain-symposium-in-amsterdam) — Source: Ensysce Biosciences
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)